Anthony E. Maida III, PhD, MA, MBA

Articles by Anthony E. Maida III, PhD, MA, MBA

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

Latest Updated Articles

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort

Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC

ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy

Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection

Identifying Which Patients With HCC Need Immunotherapy Before Liver Transplant